Annie Tang1, Caitlin M Cohan1, Genna Beattie1, Elizabeth L Cureton2, Jonathan D Svahn2, Liisa L Lyon3, Jason F Kelly4, Veronica C Shim5. 1. Department of Surgery, University of California San Francisco, East Bay, Oakland, CA, USA. 2. Department of Surgery, Kaiser Permanente Northern California, East Bay, Oakland, CA, 95611, USA. 3. The Kaiser Permanente Northern California Division of Research, Oakland, CA, 94611, USA. 4. Department of Radiation Oncology, Kaiser Permanente Northern California, East Bay, Oakland, CA, USA. 5. Department of Surgery, Kaiser Permanente Northern California, East Bay, Oakland, CA, 95611, USA. veronica.shim@kp.org.
Abstract
BACKGROUND: Patients 65 years old or older with early endocrine-responsive breast cancer have many treatment options, including no radiation. This study aimed to evaluate treatment preference when intraoperative radiation therapy (IORT) is offered in this population. METHODS: The study reviewed patients 65 years old or older with a diagnosis of early-stage endocrine-responsive breast cancer in 2016-2019 at a single hospital in a large integrated health care system. Electronic medical records of multidisciplinary breast tumor board discussion, treatment options documented by the treatment team, and final treatment offered were reviewed. Variables including age at biopsy, language, endocrine treatment, and comorbidities were collected. Regression analysis was used to evaluate for variables associated with patients' choice regarding radiation treatment. RESULTS: The institutional IORT guidelines were met by 63 patients in the described age group who had a documented offer of all radiation treatment options. The median age of the patients was 70 years (interquartile range 63-77 years). Overall, 74.6% of the patients chose IORT, and 14.3% opted for whole-breast irradiation. Only 4.8% chose to omit radiation after breast-conserving surgery, and 6.3% chose mastectomy. The patients who chose IORT were more likely to receive endocrine treatment (odds ratio 3.70; p = 0.03). Age, race, language, and comorbidities were not associated with preference for IORT (p < 0.05). CONCLUSIONS: Patients 65 years old or older with early-stage endocrine-responsive breast cancer preferred to have IORT despite counsel about the lack of survival benefit. This study suggests that local cancer control with the convenient radiation delivery method is important to the described patient population.
BACKGROUND:Patients 65 years old or older with early endocrine-responsive breast cancer have many treatment options, including no radiation. This study aimed to evaluate treatment preference when intraoperative radiation therapy (IORT) is offered in this population. METHODS: The study reviewed patients 65 years old or older with a diagnosis of early-stage endocrine-responsive breast cancer in 2016-2019 at a single hospital in a large integrated health care system. Electronic medical records of multidisciplinary breast tumor board discussion, treatment options documented by the treatment team, and final treatment offered were reviewed. Variables including age at biopsy, language, endocrine treatment, and comorbidities were collected. Regression analysis was used to evaluate for variables associated with patients' choice regarding radiation treatment. RESULTS: The institutional IORT guidelines were met by 63 patients in the described age group who had a documented offer of all radiation treatment options. The median age of the patients was 70 years (interquartile range 63-77 years). Overall, 74.6% of the patients chose IORT, and 14.3% opted for whole-breast irradiation. Only 4.8% chose to omit radiation after breast-conserving surgery, and 6.3% chose mastectomy. The patients who chose IORT were more likely to receive endocrine treatment (odds ratio 3.70; p = 0.03). Age, race, language, and comorbidities were not associated with preference for IORT (p < 0.05). CONCLUSIONS:Patients 65 years old or older with early-stage endocrine-responsive breast cancer preferred to have IORT despite counsel about the lack of survival benefit. This study suggests that local cancer control with the convenient radiation delivery method is important to the described patient population.
Authors: Ian H Kunkler; Linda J Williams; Wilma J L Jack; David A Cameron; J Michael Dixon Journal: Lancet Oncol Date: 2015-01-28 Impact factor: 41.316
Authors: Timothy J Whelan; Jean-Philippe Pignol; Mark N Levine; Jim A Julian; Robert MacKenzie; Sameer Parpia; Wendy Shelley; Laval Grimard; Julie Bowen; Himu Lukka; Francisco Perera; Anthony Fyles; Ken Schneider; Sunil Gulavita; Carolyn Freeman Journal: N Engl J Med Date: 2010-02-11 Impact factor: 91.245
Authors: YaoYao G Pollock; Amanda L Blackford; Stacie C Jeter; Jean Wright; Ashley Cimino-Mathews; Melissa Camp; Susan Harvey; Fariba Asrari; Nancy L Schoenborn; Vered Stearns Journal: Breast Cancer Res Treat Date: 2016-10-03 Impact factor: 4.872
Authors: Anthony W Fyles; David R McCready; Lee A Manchul; Maureen E Trudeau; Patricia Merante; Melania Pintilie; Lorna M Weir; Ivo A Olivotto Journal: N Engl J Med Date: 2004-09-02 Impact factor: 91.245
Authors: Richard Pötter; Michael Gnant; Werner Kwasny; Christoph Tausch; Leonore Handl-Zeller; Brigitte Pakisch; Susanne Taucher; Josef Hammer; Gero Luschin-Ebengreuth; Marianne Schmid; Felix Sedlmayer; Michael Stierer; Georg Reiner; Karin Kapp; Friedrich Hofbauer; Andrea Rottenfusser; Sabine Pöstlberger; Karin Haider; Wolfgang Draxler; Raimund Jakesz Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-23 Impact factor: 7.038
Authors: Cameron W Swanick; Xiudong Lei; Ying Xu; Yu Shen; Nathan A Goodwin; Grace L Smith; Sharon H Giordano; Kelly K Hunt; Reshma Jagsi; Simona F Shaitelman; Susan K Peterson; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2017-12-09 Impact factor: 7.038
Authors: Kevin S Hughes; Lauren A Schnaper; Jennifer R Bellon; Constance T Cirrincione; Donald A Berry; Beryl McCormick; Hyman B Muss; Barbara L Smith; Clifford A Hudis; Eric P Winer; William C Wood Journal: J Clin Oncol Date: 2013-05-20 Impact factor: 44.544
Authors: Fardeen Bhimani; Kelly Johnson; N Patrik Brodin; Wolfgang A Tomé; Jana Fox; Keyur Mehta; Maureen McEvoy; Sheldon Feldman Journal: Front Oncol Date: 2022-07-12 Impact factor: 5.738
Authors: Jayant Sharad Vaidya; Uma Jayant Vaidya; Michael Baum; Max Kishor Bulsara; David Joseph; Jeffrey S Tobias Journal: Front Oncol Date: 2022-08-11 Impact factor: 5.738